ETODOLAC

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category UNKNOWN
ATC M01AB08
UNII 2M36281008
EPA CompTox DTXSID9020615

Structure

InChI Key NNYBQONXHNTVIJ-UHFFFAOYSA-N
Smiles CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
InChI
InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)

Physicochemical Descriptors

Property Name Value
Molecular Formula C17H21NO3
Molecular Weight 287.36
AlogP 3.38
Hydrogen Bond Acceptor 2.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 4.0
Polar Surface Area 62.32
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 21.0

Metabolites Network

visNetwork

Bioactivity

Mechanism of Action Action Reference
Cyclooxygenase-2 inhibitor INHIBITOR PubMed
Protein: Cyclooxygenase-2
Description: Prostaglandin G/H synthase 2
Organism : Homo sapiens
P35354 ENSG00000073756
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Oxidoreductase
- 10300 - - 9
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Dopamine receptor
- - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 104
Assay Description Organism Bioactivity Reference
Inhibition of beta-lactamase at 100 uM None 5.0 %
Inhibitory activity against prostaglandin biosynthesis in stimulated chondrocyte cell culture None 23.0 nM
Evaluated in vitro for its ability to inhibit prostaglandin E2 production in cultured chondrocyte cells at 25 mg/kg dose Rattus norvegicus 25.0 nM
Inhibition of chymotrypsin at 250 uM unidentified 5.0 %
Inhibition of malate dehydrogenase (MDH) at 400 uM None 9.0 %
In vitro inhibition of prostaglandin E2 production in cultured chondrocytes None 23.0 nM
Inhibition against adjuvant-induced paw edema at a dose of 25 mg/kg in male Sprague-Dawley rats. Rattus norvegicus 11.2 %
Evaluated for the inhibition of adjuvant-induced hind paw edema in rats at 25 mg/kg dose Rattus norvegicus 65.0 %
In vitro inhibitory activity against ovine cyclooxygenase-1 (COX-1) at 200 uM; Inactive None 50.0 %
Inhibition of DMBA-induced/TPA-promoted skin carcinogenesis in ICR mouse assessed as reduction in tumor burden at 0.0025% topically applied qd treated one week before DMBA-TPA challenge after 20 weeks relative to control Mus musculus 40.0 %
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) None 561.0 nM
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 68.27 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 103.62 %
Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol Homo sapiens 13.0 %
Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative to SCH23390 Homo sapiens -1.4 %
Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media, using NBS plates, by OD(600) Staphylococcus aureus subsp. aureus 5.09 %
Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by OD(600) Escherichia coli -6.35 %
Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) Klebsiella pneumoniae 6.96 %
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) Pseudomonas aeruginosa -2.53 %
Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by OD600 Acinetobacter baumannii 21.05 %
Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 Candida albicans 1.19 %
Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) Cryptococcus neoformans -2.08 %

Related Entries

Cross References

Resources Reference
ChEBI 4909
ChEMBL CHEMBL622
DrugBank DB00749
DrugCentral 1103
FDA SRS 2M36281008
Human Metabolome Database HMDB0014887
Guide to Pharmacology 7185
KEGG C06991
PharmGKB PA449550
PubChem 3308
SureChEMBL SCHEMBL3903
ZINC ZINC00057313
CONTENTS